Overview

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Status:
Completed

Trial end date:
2017-07-10

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Bococizumab